Lung-MAP (SWOG S1400) is a multi-drug, multi-sub-study, biomarker-driven squamous cell lung cancer clinical trial that uses state-of-the-art genomic profiling to match patients to sub-studies testing investigational treatments that may target the genomic alterations, or mutations, found to be driving the growth of their cancer.
That means shared information and infrastructure, better access for patients to promising drugs, better access for researchers to relevant enrollees based on their genomic profiles, and less time and money needed before investigational drugs can be tested.
Find out more about how Lung-MAP is structured to benefit patients by watching the video below:
WHO WE ARE
Lung-MAP is an unprecedented public-private collaboration among: the National Cancer Institute,SWOG Cancer Research, Friends of Cancer Research, the Foundation for the National Institutes of Health, several pharmaceutical companies (Amgen, Bristol-Myers Squibb, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), Foundation Medicine and several lung cancer advocacy organizations.
OVERCOMING CURRENT HURDLES IN CLINICAL TRIALS
- Taking an investigational drug from the initial discovery stage through clinical testing and regulatory review is complicated, expensive, and inefficient.
- Trials are difficult to initiate, infrastructure-intensive, subject to lengthy regulatory review, and reliant on the enrollment of volunteers—all challenges compounded by the fact that investigational drugs are almost always tested in separate research studies, even when multiple drugs are being developed to treat the same condition.
- While the rise of precision medicine has improved many aspects of patient care, it has also exacerbated the challenges of running a clinical trial. Smaller, targeted patient populations have made it more difficult to recruit eligible patients. And reliance on multiple, single-gene diagnostic tests can increase infrastructure costs, complexity, and patient burden.
- This trial has the potential to change and accelerate the way investigational biomarker-defined therapies are tested and approved for lung cancer, and eventually for many other diseases.